Concord Biotech Ltd.NSE: CONCORDBIO

CONCORDBIO: Strong revenue growth and stable profits, with a one-time charge for regulatory changes

· Issued by Concord Biotech Ltd.

Revenue and net profit grew year-over-year for both standalone and consolidated results, with a one-time exceptional charge for new Labour Codes. A new Company Secretary was appointed, and no audit qualifications or loan defaults were reported.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.